Physician profile
Michael J Lemay
NPI 1962533380
$1,376.94
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $49.29 · 2020: $145 · 2021: $545 · 2022: $59.24 · 2023: $453 · 2024: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $578.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $577.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi US Services INC. | $325.00 | 2021 | |
| Abbott Laboratories | $299.92 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Novo Nordisk INC | $180.84 | 2020-2023 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $137.89 | 2021-2023 | Farxiga |
| Takeda Pharmaceuticals U.S.A., INC. | $125.00 | 2020 | |
| Abbvie INC. | $96.09 | 2019-2023 | |
| Dexcom, INC. | $44.93 | 2023 | Dexcom G6 Transmitter |
| Amneal Pharmaceuticals LLC | $40.54 | 2023 | Unithroid |
| Lilly USA, LLC | $25.81 | 2023 | Jardiance, Lyumjev, Baqsimi |
| Halozyme INC | $23.08 | 2023 | |
| Insulet Corporation | $22.84 | 2023 | Omnipod |
| Medtronic, INC. | $20.20 | 2023 | Minimed 780g |
| Horizon Therapeutics Plc | $18.40 | 2023 | Tepezza |
| Janssen Pharmaceuticals, INC | $16.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lemay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.